BioCardia, Inc.
US ˙ NasdaqCM ˙ US09060U5074

Introduction

This page provides a comprehensive analysis of the known insider trading history of Steven D Rubin. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

See Highest Ranking Insiders
Companies with Reported Insider Positions

The SEC filings indicate Steven D Rubin has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:RDVT / Red Violet, Inc. Director 141,138
US:ELOX / Eloxx Pharmaceuticals, Inc. Director 15,750
US:COCP / Cocrystal Pharma, Inc. Director 2,660,242
US:OPK / OPKO Health, Inc. Executive VP-Administration, Director 6,625,232
US:CDXC / ChromaDex Corporation Director 7,000
US:ROX / Castle Brands, Inc. Director 0
US:VBIV / VBI Vaccines Inc. Director 18,750
FR:IDIP / IDI Director 5,000
US:BCDA / BioCardia, Inc. Interim CEO and Interim CFO, Director 302,822
US:PBTH / Prolor Biotech, Inc. Director 0
Director 35,000
US:NIMU / Non-Invasive Monitoring Systems, Inc. Director 100,000
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Steven D Rubin. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases BCDA / BioCardia, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in BCDA / BioCardia, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

BCDA / BioCardia, Inc. Insider Trades
Insider Sales BCDA / BioCardia, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in BCDA / BioCardia, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

BCDA / BioCardia, Inc. Insider Trades
Insider Purchases COCP / Cocrystal Pharma, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in BCDA / BioCardia, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
2016-03-15 COCP Rubin Steven D 39,216 0.5100 1,867 10.7100 20,000 23 0.79 -18,525 -92.63
2015-03-25 COCP Rubin Steven D 54,348 0.9200 2,588 19.3200 50,000

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

COCP / Cocrystal Pharma, Inc. Insider Trades
Insider Sales COCP / Cocrystal Pharma, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in BCDA / BioCardia, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

COCP / Cocrystal Pharma, Inc. Insider Trades
Insider Purchases ELOX / Eloxx Pharmaceuticals, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in BCDA / BioCardia, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ELOX / Eloxx Pharmaceuticals, Inc. Insider Trades
Insider Sales ELOX / Eloxx Pharmaceuticals, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in BCDA / BioCardia, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ELOX / Eloxx Pharmaceuticals, Inc. Insider Trades
Insider Purchases NAGE / Niagen Bioscience, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in BCDA / BioCardia, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
2023-05-25 CDXC Rubin Steven D 7,000 1.4600 7,000 1.4600 10,220 315 4.3200 20,020 195.89

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

NAGE / Niagen Bioscience, Inc. Insider Trades
Insider Sales NAGE / Niagen Bioscience, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in BCDA / BioCardia, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

NAGE / Niagen Bioscience, Inc. Insider Trades
Insider Purchases NIMU / Non-Invasive Monitoring Systems, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in BCDA / BioCardia, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
2012-02-28 NIMU Rubin Steven D 100,000 0.0500 100,000 0.0500 5,000 0 0.2200 17,000 340.00

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

NIMU / Non-Invasive Monitoring Systems, Inc. Insider Trades
Insider Sales NIMU / Non-Invasive Monitoring Systems, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in BCDA / BioCardia, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

NIMU / Non-Invasive Monitoring Systems, Inc. Insider Trades
Insider Purchases OPK / OPKO Health, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in BCDA / BioCardia, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
2024-01-05 OPK Rubin Steven D 10,000 0.8669 10,000 0.8669 8,669 238 1.6800 8,131 93.79
2023-11-10 OPK Rubin Steven D 10,000 1.3000 10,000 1.3000 13,000
2020-08-26 OPK Rubin Steven D 5,000 3.9900 5,000 3.9900 19,950
2020-08-26 OPK Rubin Steven D 2,500 3.9872 2,500 3.9872 9,968
2020-08-26 OPK Rubin Steven D 2,500 4.0100 2,500 4.0100 10,025
2019-10-25 OPK Rubin Steven D 15,000 1.5000 15,000 1.5000 22,500
2019-05-09 OPK Rubin Steven D 200 2.1200 200 2.1200 424
2019-05-09 OPK Rubin Steven D 2,600 2.1300 2,600 2.1300 5,538
2019-05-09 OPK Rubin Steven D 7,200 2.1500 7,200 2.1500 15,480
2019-03-06 OPK Rubin Steven D 5,565 2.5550 5,565 2.5550 14,219
2019-03-06 OPK Rubin Steven D 2,435 2.5600 2,435 2.5600 6,234
2018-03-07 OPK Rubin Steven D 6,000 3.2500 6,000 3.2500 19,500
2017-05-31 OPK Rubin Steven D 2,000 6.1000 2,000 6.1000 12,200
2017-05-11 OPK Rubin Steven D 581 6.9000 581 6.9000 4,009
2017-05-11 OPK Rubin Steven D 1,419 6.9100 1,419 6.9100 9,805
2017-02-08 OPK Rubin Steven D 2,000 8.1070 2,000 8.1070 16,214
2016-12-30 OPK Rubin Steven D 2,000 9.1763 2,000 9.1763 18,353
2016-03-30 OPK Rubin Steven D 1,000 10.1662 1,000 10.1662 10,166
2015-08-20 OPK Rubin Steven D 200 12.3950 200 12.3950 2,479
2015-08-20 OPK Rubin Steven D 1,800 12.4000 1,800 12.4000 22,320
2013-05-01 OPK Rubin Steven D 2,500 6.4500 2,500 6.4500 16,125
2013-05-01 OPK Rubin Steven D 1,800 6.4700 1,800 6.4700 11,646
2012-03-29 OPK Rubin Steven D 2,000 4.6800 2,000 4.6800 9,360

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

OPK / OPKO Health, Inc. Insider Trades
Insider Sales OPK / OPKO Health, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in BCDA / BioCardia, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
2014-04-15 OPK Rubin Steven D 79,300 8.1036 79,300 8.1036 642,615 23 8.0100 -7,422 -1.15
2014-04-14 OPK Rubin Steven D 100,000 8.5770 100,000 8.5770 857,700

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

OPK / OPKO Health, Inc. Insider Trades
Insider Purchases RDVT / Red Violet, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in BCDA / BioCardia, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

RDVT / Red Violet, Inc. Insider Trades
Insider Sales RDVT / Red Violet, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in BCDA / BioCardia, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
2025-03-19 RDVT Rubin Steven D 10,000 38.9300 10,000 38.9300 389,300 20 34.9000 -40,300 -10.35

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

RDVT / Red Violet, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Steven D Rubin as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change		 Share
Price		 Tran
Value		 Remaining
Value
2025-03-21 2025-03-19 4 RDVT Red Violet, Inc.
Common Stock 		S - Sale -10,000 141,138 -6.62 38.93 -389,300 5,494,502
2025-01-28 2025-01-24 4 ELOX Eloxx Pharmaceuticals, Inc.
Common Stock 		M - Exercise 3,750 15,750 31.25
2024-11-05 2024-11-04 4 RDVT Red Violet, Inc.
Common Stock 		A - Award 8,000 151,138 5.59
2024-10-17 2024-10-16 4 ELOX Eloxx Pharmaceuticals, Inc.
Common Stock 		A - Award 12,000 12,000
2024-10-11 2024-10-09 4 COCP Cocrystal Pharma, Inc.
Common Stock 		A - Award 18,957 2,660,242 0.72
2024-07-26 2024-07-24 4 OPK OPKO HEALTH, INC.
Common Stock 		A - Award 437,500 6,625,232 7.07
2024-01-05 2024-01-05 4 OPK OPKO HEALTH, INC.
Common Stock 		P - Purchase 10,000 6,187,732 0.16 0.87 8,669 5,364,145
2023-12-04 2023-11-30 4 RDVT Red Violet, Inc.
Common Stock 		A - Award 10,800 143,138 8.16
2023-11-13 2023-11-10 4 OPK OPKO HEALTH, INC.
Common Stock 		P - Purchase 10,000 6,177,732 0.16 1.30 13,000 8,031,052
2023-05-30 2023-05-25 4 CDXC ChromaDex Corp.
Common Stock 		P - Purchase 7,000 7,000 1.46 10,220 10,220
2022-10-13 2022-10-12 4 RDVT Red Violet, Inc.
Common Stock 		A - Award 10,800 132,338 8.89
2021-09-27 2021-09-24 4 RDVT Red Violet, Inc.
Common Stock 		A - Award 8,900 121,538 7.90
2021-07-20 2021-07-16 4 COCP Cocrystal Pharma, Inc.
Stock Options (Right to Buy) 		A - Award 88,000 88,000
2021-06-22 2021-06-17 4 CDXC ChromaDex Corp.
Stock Options (right to buy) 		A - Award 20,000 20,000
2021-05-20 2021-05-19 4 ELOX Eloxx Pharmaceuticals, Inc.
Stock Option (Right to Buy) 		A - Award 20,000 20,000
2021-02-22 2021-02-19 4 OPK OPKO HEALTH, INC.
Stock Option (Right to Buy) 		A - Award 350,000 350,000
2020-11-24 2020-11-20 4 RDVT Red Violet, Inc.
Common Stock 		A - Award 7,000 112,638 6.63
2020-08-27 2020-08-26 4 OPK OPKO HEALTH, INC.
Common Stock 		P - Purchase 2,500 6,167,732 0.04 4.01 10,025 24,732,605
2020-08-27 2020-08-26 4 OPK OPKO HEALTH, INC.
Common Stock 		P - Purchase 2,500 6,165,232 0.04 3.99 9,968 24,582,013
2020-08-27 2020-08-26 4 OPK OPKO HEALTH, INC.
Common Stock 		P - Purchase 5,000 6,162,732 0.08 3.99 19,950 24,589,301
2020-06-24 2020-06-22 4 COCP Cocrystal Pharma, Inc.
Stock Options (Right to Buy) 		A - Award 72,000 72,000
2020-06-23 2020-06-19 4 CDXC ChromaDex Corp.
Stock Options (right to buy) 		A - Award 20,000 20,000
2020-06-08 2020-06-04 4 OPK Opko Health, Inc.
Stock Option (Right to Buy) 		A - Award 350,000 350,000
2020-05-26 2020-05-20 4 ELOX Eloxx Pharmaceuticals, Inc.
Stock Option (Right to Buy) 		A - Award 20,000 20,000
2019-10-30 2019-10-28 4 RDVT Red Violet, Inc.
Common Stock 		A - Award 12,500 105,638 13.42
2019-10-25 2019-10-25 4 OPK Opko Health, Inc.
Common Stock 		P - Purchase 15,000 5,744,147 0.26 1.50 22,500 8,616,220
2019-10-25 2019-07-01 4 OPK Opko Health, Inc.
Stock Option (Right to Buy) 		A - Award 250,000 250,000
2019-10-09 2019-10-08 4 ROX Castle Brands Inc
Stock Option (Right to Buy) 		D - Sale to Issuer -20,000 0 -100.00
2019-10-09 2019-10-08 4 ROX Castle Brands Inc
Stock Option (Right to Buy) 		D - Sale to Issuer -20,000 0 -100.00
2019-10-09 2019-10-08 4 ROX Castle Brands Inc
Stock Option (Right to Buy) 		D - Sale to Issuer -20,000 0 -100.00
2019-10-09 2019-10-08 4 ROX Castle Brands Inc
Stock Option (Right to Buy) 		D - Sale to Issuer -20,000 0 -100.00
2019-10-09 2019-10-08 4 ROX Castle Brands Inc
Stock Option (Right to Buy) 		D - Sale to Issuer -20,000 0 -100.00
2019-10-09 2019-10-08 4 ROX Castle Brands Inc
Stock Option (Right to Buy) 		D - Sale to Issuer -20,000 0 -100.00
2019-10-09 2019-10-08 4 ROX Castle Brands Inc
Stock Option (Right to Buy) 		D - Sale to Issuer -20,000 0 -100.00
2019-10-09 2019-10-08 4 ROX Castle Brands Inc
Common Stock 		D - Sale to Issuer -22,500 0 -100.00 1.27 -28,575
2019-10-09 2019-10-08 4 ROX Castle Brands Inc
Common Stock 		U - Other -108,500 22,500 -82.82 1.27 -137,795 28,575
2019-08-05 2019-08-01 4 RDVT Red Violet, Inc.
Common Stock 		A - Award 8,334 68,472 13.86
2019-08-05 2019-08-01 4 RDVT Red Violet, Inc.
Common Stock 		A - Award 25,000 25,000
2019-07-03 2019-07-01 4 OPK Opko Health, Inc.
Stock Option (Right to Buy) 		A - Award 250,000 250,000
2019-06-24 2019-06-21 4 CDXC ChromaDex Corp.
Stock Options (right to buy) 		A - Award 20,000 20,000
2019-05-29 2019-05-29 4 ELOX Eloxx Pharmaceuticals, Inc.
Stock Option (Right to Buy) 		A - Award 20,000 20,000
2019-05-10 2019-05-09 4 OPK Opko Health, Inc.
Common Stock 		P - Purchase 7,200 5,729,147 0.13 2.15 15,480 12,317,666
2019-05-10 2019-05-09 4 OPK Opko Health, Inc.
Common Stock 		P - Purchase 2,600 5,721,947 0.05 2.13 5,538 12,187,747
2019-05-10 2019-05-09 4 OPK Opko Health, Inc.
Common Stock 		P - Purchase 200 5,719,347 0.00 2.12 424 12,125,016
2019-03-07 2019-03-06 4 OPK Opko Health, Inc.
Common Stock 		P - Purchase 2,435 5,719,147 0.04 2.56 6,234 14,641,016
2019-03-07 2019-03-06 4 OPK Opko Health, Inc.
Common Stock 		P - Purchase 5,565 5,716,712 0.10 2.56 14,219 14,606,199
2019-03-01 2019-02-27 4 ROX Castle Brands Inc
Common Stock 		A - Award 15,000 131,000 12.93
2019-02-05 2019-02-01 4 OPK Opko Health, Inc.
Stock Option (Right to Buy) 		M - Exercise -24,877 0 -100.00
2019-02-05 2019-02-01 4 OPK Opko Health, Inc.
Common Stock 		F - Taxes -5,645 5,711,147 -0.10 3.59 -20,266 20,503,018
2019-02-05 2019-02-01 4 OPK Opko Health, Inc.
Common Stock 		M - Exercise 24,877 5,716,792 0.44 0.66 16,419 3,773,083
2019-01-18 2019-01-16 4 ROX Castle Brands Inc
Stock Option (Right to Buy) 		M - Exercise -100,000 0 -100.00
2019-01-18 2019-01-16 4 ROX Castle Brands Inc
Common Stock 		M - Exercise 100,000 116,000 625.00 0.23 23,000 26,680
2018-09-24 2018-09-21 4 COCP Cocrystal Pharma, Inc.
Stock Options (Right to Buy) 		A - Award 50,000 50,000
2018-06-26 2018-06-22 4 CDXC ChromaDex Corp.
Stock Options (right to buy) 		A - Award 20,000 20,000
2018-06-22 2018-06-21 4 OPK Opko Health, Inc.
Stock Option (Right to Buy) 		A - Award 300,000 300,000
2018-06-19 2018-06-15 4 ELOX Eloxx Pharmaceuticals, Inc.
Stock Option (Right to Buy) 		A - Award 40,000 40,000
2018-06-18 2018-06-14 4 VBIV VBI Vaccines Inc/BC
Restricted Stock Units (RSUs) 		M - Exercise -18,750 18,750 -50.00
2018-06-18 2018-06-14 4 VBIV VBI Vaccines Inc/BC
Common Shares, no par value per share 		M - Exercise 18,750 56,250 50.00
2018-04-02 2018-03-29 4 RDVT Red Violet, Inc.
Common Stock 		A - Award 8,000 4,000 -200.00
2018-04-02 2018-03-29 4 RDVT Red Violet, Inc.
Common Stock 		A - Award 12,000 12,000
2018-03-30 3 RDVT Red Violet, Inc.
Common Stock 		96,276
2018-03-30 3 RDVT Red Violet, Inc.
Common Stock 		96,276
2018-03-30 3 RDVT Red Violet, Inc.
Common Stock 		96,276
2018-03-08 2018-03-07 4 OPK Opko Health, Inc.
Common Stock 		P - Purchase 6,000 5,691,915 0.11 3.25 19,500 18,498,724
2018-03-05 2018-03-01 4 ROX Castle Brands Inc
Common Stock 		A - Award 15,000 16,000 1,500.00
2018-01-25 2018-01-23 4 VBIV VBI Vaccines Inc/BC
Option (Right to Buy Common Shares) 		A - Award 75,000 75,000
2017-12-21 2017-12-19 4 SVOND Sevion Therapeutics, Inc.
Common Stock Option (Right to Buy) 		A - Award 43,189 43,189
2017-07-05 2017-06-20 4 CDXC ChromaDex Corp.
Stock Options (right to buy) 		A - Award 20,000 20,000
2017-06-16 2017-06-14 4 VBIV VBI Vaccines Inc/BC
Restricted Stock Units (RSUs) 		M - Exercise -18,750 37,500 -33.33
2017-06-16 2017-06-14 4 VBIV VBI Vaccines Inc/BC
Common Shares, no par value per share 		M - Exercise 18,750 37,500 100.00
2017-06-01 2017-05-31 4 OPK Opko Health, Inc.
Common Stock 		P - Purchase 2,000 5,685,915 0.04 6.10 12,200 34,684,082
2017-05-11 2017-05-11 4 OPK Opko Health, Inc.
Common Stock 		P - Purchase 1,419 5,683,915 0.02 6.91 9,805 39,275,853
2017-05-11 2017-05-11 4 OPK Opko Health, Inc.
Common Stock 		P - Purchase 581 5,682,496 0.01 6.90 4,009 39,209,222
2017-04-17 2017-04-13 4 COGT Cogint, Inc.
Common Stock 		A - Award 5,000 5,000
2017-04-17 2017-04-13 4 COGT Cogint, Inc.
Common Stock 		A - Award 20,000 20,000
2017-04-13 2017-04-12 4 OPK Opko Health, Inc.
Stock Option (Right to Buy) 		M - Exercise -265,000 0 -100.00
2017-04-13 2017-04-12 4 OPK Opko Health, Inc.
Common Stock 		F - Taxes -158,336 5,681,915 -2.71 7.66 -1,212,854 43,523,469
2017-04-13 2017-04-12 4 OPK Opko Health, Inc.
Common Stock 		M - Exercise 265,000 5,840,251 4.75 2.36 625,400 13,782,992
2017-04-07 2017-04-06 4 CDXC ChromaDex Corp.
Employee Stock Options (right to buy) 		A - Award 40,000 40,000
2017-03-31 2017-03-30 4 VBIV VBI Vaccines Inc/BC
Option (Right to Buy Common Shares) 		A - Award 12,500 12,500
2017-03-31 3 VBIV VBI Vaccines Inc/BC
Common Shares, no par value per share 		37,500
2017-03-31 3 VBIV VBI Vaccines Inc/BC
Common Shares, no par value per share 		37,500
2017-03-01 2017-02-28 4 ROX Castle Brands Inc
Stock Option (Right to Buy) 		A - Award 20,000 20,000
2017-02-16 2017-02-14 4 SVON Sevion Therapeutics, Inc.
Company Stock Option 		A - Award 160,227 160,227 0.11 17,625 17,625
2017-02-09 2017-02-08 4 OPK Opko Health, Inc.
Common Stock 		P - Purchase 2,000 5,575,251 0.04 8.11 16,214 45,198,560
2017-01-03 2016-12-30 4 OPK Opko Health, Inc.
Common Stock 		P - Purchase 2,000 5,573,251 0.04 9.18 18,353 51,141,823
2016-08-12 2016-08-11 4 CDOM Tiger X Medical, Inc.
Common Stock 		A - Award 200,000 302,822 194.51
2016-06-15 2016-06-13 4 SVON Sevion Therapeutics, Inc.
Company Stock Option 		A - Award 89,773 89,773 0.11 9,875 9,875
2016-06-03 2016-06-01 4 IDI IDI, Inc.
Common Stock 		A - Award 100,000 100,000
2016-05-17 2016-05-03 4/A OPK Opko Health, Inc.
Common Stock 		F - Taxes -121,156 5,571,251 -2.13 10.34 -1,252,753 57,606,735
2016-05-05 2016-05-03 4 OPK Opko Health, Inc.
Stock Option (Right to Buy) 		M - Exercise -250,000 0 -100.00
2016-05-05 2016-05-03 4 OPK Opko Health, Inc.
Common Stock 		F - Taxes -134,918 5,557,489 -2.37 10.34 -1,395,052 57,464,436
2016-05-05 2016-05-03 4 OPK Opko Health, Inc.
Common Stock 		M - Exercise 250,000 5,692,407 4.59 1.16 290,000 6,603,192
2016-04-01 2016-04-01 4 OPK Opko Health, Inc.
Stock Option (Right to Buy) 		A - Award 450,000 450,000
2016-03-31 2016-03-30 4 OPK Opko Health, Inc.
Common Stock 		P - Purchase 1,000 5,442,407 0.02 10.17 10,166 55,328,598
2016-03-21 2016-03-17 4 ROX Castle Brands Inc
Stock Option (Right to Buy) 		A - Award 20,000 20,000
2016-03-18 2016-03-15 4/A COCP Cocrystal Pharma, Inc.
Common Stock 		P - Purchase 39,216 733,484 5.65 0.51 20,000 374,077
2016-03-17 2016-03-15 4 COCP Cocrystal Pharma, Inc.
Common Stock 		P - Purchase 39,216 93,564 72.16 0.51 20,000 47,718
2015-11-23 2015-11-19 4 SVON Sevion Therapeutics, Inc.
Company Stock Option 		A - Award 40,000 40,000 0.25 10,000 10,000
2015-09-25 2015-09-24 4 IDI IDI, Inc.
Restricted Stock Units 		M - Exercise -73,000 0 -100.00
2015-09-25 2015-09-24 4 IDI IDI, Inc.
Common Stock 		M - Exercise 73,000 163,255 80.88
2015-08-20 2015-08-20 4 OPK Opko Health, Inc.
Common Stock 		P - Purchase 1,800 5,441,407 0.03 12.40 22,320 67,473,447
2015-08-20 2015-08-20 4 OPK Opko Health, Inc.
Common Stock 		P - Purchase 200 5,439,607 0.00 12.40 2,479 67,423,929
2015-07-30 2015-07-28 4 IDI IDI, Inc.
Restricted Stock Units 		M - Exercise -27,000 0 -100.00
2015-07-30 2015-07-28 4 IDI IDI, Inc.
Common Stock 		M - Exercise 27,000 90,255 42.68
2015-06-03 2015-06-02 4 IDI IDI, Inc.
Common Stock 		A - Award 75,000 75,000
2015-04-15 2015-04-13 4 COCP Cocrystal Pharma, Inc.
Stock options (Right to buy) 		A - Award 350,000 350,000
2015-03-27 2015-03-25 4 COCP Cocrystal Pharma, Inc.
Common Stock 		P - Purchase 54,348 694,268 8.49 0.92 50,000 638,727
2015-03-27 2015-03-26 4 ROX Castle Brands Inc
Stock Option (Right to Buy) 		A - Award 20,000 20,000
2015-03-24 2015-03-24 4 IDI Tiger Media, Inc.
Restricted Stock Units 		A - Award 73,000 73,000
2015-03-24 3 IDI Tiger Media, Inc.
Common Stock 		126,510
2015-03-24 3 IDI Tiger Media, Inc.
Common Stock 		126,510
2015-03-19 2015-03-18 4 OPK Opko Health, Inc.
Stock Option (Right to Buy) 		A - Award 450,000 450,000
2015-03-05 2015-03-03 4 COCP Cocrystal Pharma, Inc.
Series B Convertible Preferred Stock 		M - Exercise -536 0 -100.00
2015-03-05 2015-03-03 4 COCP Cocrystal Pharma, Inc.
Common Stock 		M - Exercise 109,920 639,920 20.74
2015-02-02 2015-01-31 4 OPK Opko Health, Inc.
Warrant (Right to Buy) 		M - Exercise -22,125 0 -100.00
2015-02-02 2015-01-31 4 OPK Opko Health, Inc.
Warrant (Right to Buy) 		M - Exercise -22,124 0 -100.00
2015-02-02 2015-01-31 4 OPK Opko Health, Inc.
Warrant (Right to Buy) 		M - Exercise -22,124 0 -100.00
2015-02-02 2015-01-31 4 OPK Opko Health, Inc.
Warrant (Right to Buy) 		M - Exercise -6,487 0 -100.00
2015-02-02 2015-01-31 4 OPK Opko Health, Inc.
Warrant (Right to Buy) 		M - Exercise -81,085 0 -100.00
2015-02-02 2015-01-31 4 OPK Opko Health, Inc.
Warrant (Right to Buy) 		M - Exercise -4,000,000 0 -100.00
2015-02-02 2015-01-31 4 OPK Opko Health, Inc.
Warrant (Right to Buy) 		M - Exercise -345,480 0 -100.00
2015-02-02 2015-01-31 4 OPK Opko Health, Inc.
Warrant (Right to Buy) 		M - Exercise -345,480 0 -100.00
2015-02-02 2015-01-31 4 OPK Opko Health, Inc.
Warrant (Right to Buy) 		M - Exercise -345,480 0 -100.00
2015-02-02 2015-01-31 4 OPK Opko Health, Inc.
Common Stock 		F - Taxes -21,523 20,091,062 -0.11 11.62 -250,011 233,377,776
2015-02-02 2015-01-31 4 OPK Opko Health, Inc.
Common Stock 		F - Taxes -174,119 20,112,585 -0.86 11.78 -2,050,599 236,865,914
2015-02-02 2015-01-31 4 OPK Opko Health, Inc.
Common Stock 		M - Exercise 81,085 20,286,704 0.40 0.00 154 38,545
2015-02-02 2015-01-31 4 OPK Opko Health, Inc.
Common Stock 		M - Exercise 648,700 20,205,619 3.32 0.39 250,009 7,787,246
2015-02-02 2015-01-31 4 OPK Opko Health, Inc.
Common Stock 		M - Exercise 4,000,000 19,556,919 25.71 0.50 1,993,600 9,747,168
2015-02-02 2015-01-31 4 OPK Opko Health, Inc.
Common Stock 		M - Exercise 22,124 15,556,919 0.14 0.67 14,885 10,466,695
2015-02-02 2015-01-31 4 OPK Opko Health, Inc.
Common Stock 		M - Exercise 22,124 15,534,795 0.14 0.85 18,746 13,162,632
2015-02-02 2015-01-31 4 OPK Opko Health, Inc.
Common Stock 		M - Exercise 22,125 15,512,671 0.14 1.05 23,156 16,235,561
2015-02-02 2015-01-31 4 OPK Opko Health, Inc.
Common Stock 		F - Taxes -75,299 5,439,407 -1.37 11.78 -886,796 64,059,896
2015-02-02 2015-01-31 4 OPK Opko Health, Inc.
Common Stock 		M - Exercise 345,480 5,514,706 6.68 1.05 361,579 5,771,691
2015-02-02 2015-01-31 4 OPK Opko Health, Inc.
Common Stock 		M - Exercise 345,480 5,169,226 7.16 0.85 292,725 4,379,885
2015-02-02 2015-01-31 4 OPK Opko Health, Inc.
Common Stock 		M - Exercise 345,480 4,823,746 7.71 0.67 232,439 3,245,416
2014-11-20 2014-11-18 4 SVON Sevion Therapeutics, Inc.
Common Stock Option (right to buy) 		A - Award 3,314 28,658 13.08 0.42 1,392 12,036
2014-11-20 2014-11-18 4 SVON Sevion Therapeutics, Inc.
Common Stock Option (right to buy) 		A - Award 25,344 25,344
2014-04-15 2014-04-15 4 OPK Opko Health, Inc.
Common Stock 		S - Sale -79,300 4,478,266 -1.74 8.10 -642,615 36,290,076
2014-04-15 2014-04-14 4 OPK Opko Health, Inc.
Stock Option (Right to Buy) 		A - Award 350,000 350,000
2014-04-15 2014-04-14 4 OPK Opko Health, Inc.
Common Stock 		S - Sale -100,000 4,557,566 -2.15 8.58 -857,700 39,090,244
2014-04-15 2014-04-11 4 OPK Opko Health, Inc.
Stock Option (Right to Buy) 		M - Exercise -200,000 0 -100.00
2014-04-15 2014-04-11 4 OPK Opko Health, Inc.
Stock Option (Right to Buy) 		M - Exercise -500,000 0 -100.00
2014-04-15 2014-04-11 4 OPK Opko Health, Inc.
Common Stock 		F - Taxes -312,289 4,657,566 -6.28 8.87 -2,770,003 41,312,610
2014-04-15 2014-04-11 4 OPK Opko Health, Inc.
Common Stock 		M - Exercise 200,000 4,969,855 4.19 1.65 330,000 8,200,261
2014-04-15 2014-04-11 4 OPK Opko Health, Inc.
Common Stock 		M - Exercise 500,000 4,769,855 11.71 4.88 2,440,000 23,276,892
2014-03-17 3 BZNE BIOZONE PHARMACEUTICALS, INC.
Common Stock 		5,605,993
2014-03-17 3 BZNE BIOZONE PHARMACEUTICALS, INC.
Common Stock 		9,621,986
2014-03-17 3 BZNE BIOZONE PHARMACEUTICALS, INC.
Common Stock 		5,605,993
2014-03-17 3 BZNE BIOZONE PHARMACEUTICALS, INC.
Common Stock 		9,621,986
2014-03-07 2014-03-05 4 ROX Castle Brands Inc
Stock Option (Right to Buy) 		A - Award 20,000 20,000
2013-09-03 2013-08-29 4 OPK Opko Health, Inc.
Stock Option (Right to Buy) 		A - Award 24,877 24,877
2013-09-03 2013-08-29 4 OPK Opko Health, Inc.
Stock Option (Right to Buy) 		A - Award 24,877 24,877
2013-09-03 2013-08-29 4 OPK Opko Health, Inc.
Stock Option (Right to Buy) 		A - Award 308,481 308,481
2013-09-03 2013-08-29 4 OPK Opko Health, Inc.
Common Stock 		A - Award 74,387 4,269,855 1.77
2013-09-03 2013-08-29 4 PBTH PROLOR Biotech, Inc.
Stock Option (right to buy) 		D - Sale to Issuer -310,000 0 -100.00
2013-09-03 2013-08-29 4 PBTH PROLOR Biotech, Inc.
Stock Option (right to buy) 		D - Sale to Issuer -25,000 0 -100.00
2013-09-03 2013-08-29 4 PBTH PROLOR Biotech, Inc.
Stock Option (right to buy) 		D - Sale to Issuer -25,000 0 -100.00
2013-09-03 2013-08-29 4 PBTH PROLOR Biotech, Inc.
Common Stock 		D - Sale to Issuer -74,753 0 -100.00
2013-06-06 2013-06-04 4 PBTH PROLOR Biotech, Inc.
Stock Option (right to buy) 		A - Award 310,000 310,000
2013-05-02 2013-05-01 4 OPK Opko Health, Inc.
Common Stock 		P - Purchase 1,800 4,195,468 0.04 6.47 11,646 27,144,678
2013-05-02 2013-05-01 4 OPK Opko Health, Inc.
Common Stock 		P - Purchase 2,500 4,193,668 0.06 6.45 16,125 27,049,159
2013-04-25 2013-04-23 4 SFES.OB SafeStitch Medical, Inc.
Stock Option (Right to Buy) 		A - Award 35,000 35,000
2013-03-20 2013-03-18 4 OPK Opko Health, Inc.
Stock Option (Right to Buy) 		A - Award 450,000 450,000
2012-10-29 2012-10-25 4 SFES SafeStitch Medical, Inc.
Warrants 		X - Other -785,383 0 -100.00
2012-10-29 2012-10-25 4 SFES SafeStitch Medical, Inc.
Common Stock 		X - Other 785,383 785,383 0.25 196,346 196,346
2012-10-17 2012-10-15 4 ROX Castle Brands Inc
Stock Option (Right to Buy) 		A - Award 20,000 20,000
2012-04-12 2012-04-12 4 PBTH PROLOR Biotech, Inc.
Common Stock Warrants (right to buy) 		X - Other -1,667 0 -100.00
2012-04-12 2012-04-12 4 PBTH PROLOR Biotech, Inc.
Common Stock 		X - Other 1,667 74,753 2.28 2.50 4,168 186,882
2012-03-30 2012-03-29 4 OPK Opko Health, Inc.
Common Stock 		P - Purchase 2,000 4,191,168 0.05 4.68 9,360 19,614,666
2012-03-01 2012-02-28 4 NIMU NON INVASIVE MONITORING SYSTEMS INC /FL/
Common Stock, $0.01 par value 		P - Purchase 100,000 100,000 0.05 5,000 5,000
2012-02-17 2012-02-16 4 SFES SafeStitch Medical, Inc.
Stock Option (Right to Buy) 		A - Award 25,000 25,000
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)